HONG KONG, Feb. 6, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technologies and marketing networks to enhance its business partners' sales growth and commercial value, today announced that it has received the "High-Quality Listed Company Award" under the 2025 Caiwen Awards, in recognition of its performance in business strategy upgrades and sustainable value creation. The "High-Quality Listed C ...

Under the agreement, CFFM will purchase Pulsenmore ES home ultrasound services, enabling patients to benefit from remote monitoring while reducing unnecessary visits to the diagnostic center. Pulsenmore redefines prenatal care through clinically validated home ultrasound and telehealth technology, addressing one of the fastest-growing needs in global healthcare: high-quality care delivered beyond the clinic. Positioned at the intersection of digital health, telemedicine, and femtech, Pulsenmore enables rem ...

Core Viewpoint - CIMG Inc. has announced a sales agreement through its subsidiary, Zhimeng, to supply wood chips to Yuncheng Trading, which is expected to stabilize the company's raw material supply chain and positively impact its financial performance [1][2][3]. Group 1: Sales Agreement Details - Zhimeng will supply approximately 15,000 bone-dry metric tons of wood chips, including eucalyptus, acacia, and mixed wood chips, to Yuncheng Trading, with a total contract value of approximately US$2.59 million [2]. - The delivery is expected to be completed by February 28, 2026, with a variance allowance of up to 10% on the total quantity [2]. Group 2: Strategic Implications - The sales agreement is aimed at establishing long-term, stable relationships with both upstream and downstream partners, aligning with the company's strategic development objectives [3]. - The company reports steady performance growth across all business lines, indicating a sound operational status [3]. Group 3: Company Overview - CIMG specializes in digital health and sales development, leveraging technologies and marketing networks to enhance business partners' sales growth [1]. - The company employs AI and cryptocurrencies to drive business growth, with a client portfolio that includes brands such as Kangduoyuan and Maca-Noni [4].

Core Viewpoint - Reliance Global Group is changing its ticker symbol from "RELI" to "EZRA" to better reflect its strategic evolution towards technology-focused acquisitions [1] Group 1: Ticker Symbol Change - The ticker symbol change will be effective at the open of trading on January 26 [1] - The company's common stock will continue to be listed on NASDAQ, and the CUSIP number will remain unchanged [1] Group 2: Strategic Evolution - The change is part of the formation of EZRA International Group, which will focus on acquiring controlling stakes in technology companies [1] - Initial emphasis will be on sectors such as cybersecurity, artificial intelligence, data analytics, FinTech, InsurTech, MedTech, and digital health [1] Group 3: Acquisition Plans - The company plans to acquire a majority stake in Scentech, an AI diagnostics company [1] - The Scentech transaction is structured around clinical, regulatory, and operational milestones [1] - This acquisition represents the first anticipated move under EZRA International Group, aiming for high-impact, technology-driven opportunities with significant long-term potential [1]

Industry Overview - The Medical Info Systems industry is rapidly expanding due to innovations in healthcare resource management, patient data handling, and integrated digital care delivery [1] - Companies in this industry develop and market healthcare information systems, providing software and hardware solutions for secure access to real-time clinical, administrative, and financial data [4] Market Growth and Trends - The use of artificial intelligence (AI) in healthcare is projected to grow at a CAGR of 38.6% from 2025 to 2030, driven by demand for enhanced diagnostic accuracy and personalized medicine [2] - The global Smart Healthcare Products market was valued at $280.48 billion in 2024 and is expected to reach $796.36 billion by 2032, growing at a CAGR of 15.37% [5] - Remote patient monitoring and telehealth services are experiencing significant growth due to increased awareness of continuous patient monitoring devices [5] Key Players - Doximity (DOCS) is a market leader in physician engagement, covering over 80% of U.S. doctors, with a subscription-based revenue model and a total addressable market of $18.55 billion [17] - 10x Genomics (TXG) develops products for analyzing biological systems, with a Zacks Consensus Estimate indicating a 72.4% improvement in earnings from 2024 to 2025 [21][22] - Omnicell (OMCL) focuses on medication management solutions and is expected to achieve a revenue CAGR of 2.8% from 2025 to 2027 [25] Financial Performance - The Medical Info Systems industry has underperformed the S&P 500 and the Zacks Medical sector, losing 7.7% over the past year compared to the sector's growth of 24.7% [11] - The industry is currently trading at a forward price-to-sales (P/S) ratio of 4.65X, lower than the S&P 500's 5.65X and the sector's 2.35X [14] Cybersecurity Concerns - As healthcare systems become more digital, cybersecurity has emerged as a critical concern, with rising instances of ransomware and cyberattacks targeting healthcare organizations [7][8]

Core Insights - NeuralCloud Solutions Inc. has announced a strategic collaboration with Movesense Ltd to enhance cardiac monitoring solutions through the integration of wearable ECG devices and AI technology [1][2]. Group 1: Collaboration Overview - The partnership designates Movesense as a primary ECG device partner for NeuralCloud, focusing on developing bundled cardiac monitoring solutions [1]. - The collaboration aims to combine Movesense's wearable single-lead ECG sensors with NeuralCloud's AI-powered platforms, including MaxYield™, CardioYield™, and Insight360™, to improve ECG acquisition and reporting [2][4]. Group 2: Technology and Product Integration - Movesense's lightweight and programmable wearable sensors provide a flexible and cost-effective hardware foundation for ECG monitoring [3]. - The integration of Movesense's sensors with NeuralCloud's AI-driven signal processing allows for comprehensive ECG workflows that surpass traditional methods [3][4]. - Insight360™ offers customizable ECG reports through user-friendly dashboards, while CardioYield™ facilitates structured Holter-style reviews, and MaxYield™ enhances signal quality and data labeling [5]. Group 3: Market Position and Strategy - The collaboration aims to address markets traditionally served by higher-cost Holter monitoring systems, potentially offering more accessible alternatives [4]. - The partnership enhances operational and commercial flexibility, enabling faster deployment and broader market reach for combined hardware and software solutions [6]. - The collaboration reflects a strategic move to embed AI-powered cardiac intelligence into real-world workflows, strengthening the companies' market position [6].

Summary of Aptar's Presentation at the 44th Annual JPMorgan Healthcare Conference Company Overview - **Company**: Aptar - **Industry**: Healthcare, specifically focusing on drug delivery systems, beauty, and closures - **Key Executives Present**: Stephan Tanda (CEO), Vanessa Kanu (CFO), Gael Touya (President, Aptar Pharma), Mary Skafidas (SVP, Investor Relations and Communications) [1] Core Business Segments - **Pharma Business**: Represents 46% of total company revenue and contributes two-thirds of EBITDA, with a growth rate of 7% [2][4] - **Beauty and Closures**: These segments are also performing well, with significant improvements noted [2][48] Financial Performance and Strategy - **Capital Allocation**: The company maintains a balanced approach, with approximately 70% of capital invested in growth and 30% returned to shareholders through dividends and share buybacks [5][44] - **Dividends**: Aptar has a history of 32 years of increasing dividends, supported by growing cash flow [5] - **Share Repurchases**: Increased activity in share buybacks, with $270 million remaining in authorization expected to be utilized [5][45] Market Dynamics and Growth Opportunities - **Total Addressable Market (TAM)**: The company is focused on large and growing markets, with Pharma leading at a 7% growth rate, Beauty at 4%, and Closures at 2% [4] - **Pipeline Growth**: Since 2019, the average weighted value of Aptar's pipeline has increased by 54%, with the number of opportunities growing by 46% [10] - **Innovative Drug Delivery**: The company is pioneering systemic nasal drug delivery, which allows for direct administration into the bloodstream, bypassing the gastrointestinal tract [11][12] Product Innovations - **Nasal Delivery Systems**: Significant advancements in drug delivery through the nasal route, including treatments for neurological disorders and chronic diseases [12][17] - **Injectables**: The injectables segment is expected to grow significantly, driven by demand for GLP-1 medications and vaccines [19][20] - **Digital Health Solutions**: Partnerships, such as with Oura, enhance patient engagement and adherence through technology [24][43] Regulatory and Competitive Position - **Regulatory Expertise**: Aptar's deep regulatory knowledge is a competitive advantage, allowing for successful navigation of the drug approval process [6][7] - **Intellectual Property**: The company emphasizes the importance of its IP portfolio, which includes patents and trade secrets, as a core component of its business strategy [28][29] Challenges and Market Adjustments - **Narcan Market Dynamics**: The company anticipates a normalization period following a surge in Narcan sales, with a projected $65 million headwind expected in the first half of 2026 due to inventory adjustments [30][33] - **Supply Chain Strategy**: Aptar's four-region supply chain strategy positions it well to meet market demands amid geopolitical challenges [20] Conclusion - **Overall Outlook**: Aptar is well-positioned for growth with a strong pipeline, innovative drug delivery solutions, and a commitment to sustainability and patient-centric approaches [24][42]

Industry Overview - The health and fitness industry has transformed into a significant global movement driven by a shift towards healthier living, with consumers seeking balanced nutrition and structured exercise routines [2] - Demand is increasing across gyms, supplements, and customized wellness programs, aided by technology that enhances personal health management through wearables and virtual coaching [2] - The global health and wellness market is projected to reach $11 trillion by 2034, growing at a 5.4% CAGR from 2025, driven by preventive care initiatives and workplace wellness programs [4] Key Players - Apple is enhancing its health and fitness offerings through the Apple Watch ecosystem and Fitness+ platform, integrating activity tracking with guided workouts [3] - Amazon is expanding its healthcare presence via One Medical, utilizing AI tools to improve access and convenience in health services [3] - United Natural Foods (UNFI) focuses on supplying natural and organic products that support healthier lifestyles, providing a range of groceries and wellness products [7][8] - The Vita Coco Company develops functional beverages, including coconut water and protein-infused drinks, aligning with health and fitness trends [11][12] - Doximity offers a digital platform for healthcare professionals, enhancing efficiency in healthcare delivery with tools for telehealth and administrative tasks [14][15] - Peloton Interactive combines high-end fitness equipment with digital content and community engagement, evolving towards a subscription-based model [17][19] Company Strategies - UNFI has adapted to consumer preferences for clean-label foods and has invested in distribution infrastructure to enhance efficiency and scale [8][9] - Vita Coco has expanded its product line to include fitness-focused beverages while maintaining brand leadership in the coconut water category [12][13] - Doximity has evolved into a comprehensive health technology solution, integrating telehealth and workflow tools to support healthcare professionals [15][16] - Peloton has shifted its strategy to emphasize subscription revenues, expanding its content library and diversifying distribution channels to reach a broader audience [19][20]

Core Insights - Butterfly Network, Inc. anticipates a revenue growth of at least 17% year-over-year for the fourth quarter ending December 31, 2025 [1] - The company is entering 2026 with strong momentum in its handheld ultrasound business and plans to outline its growth strategy at the upcoming J.P. Morgan Healthcare Conference [2] Company Overview - Butterfly Network is a digital health company focused on transforming medical imaging through its proprietary Ultrasound-on-Chip™ technology and software solutions [3] - The company launched the first handheld, single-probe, whole-body ultrasound system, Butterfly iQ, in 2018, followed by the iQ+ in 2020 and the iQ3 in 2024, each improving in processing power and performance [3] - The iQ3 received the Best Medical Technology award at the 2024 Prix Galien USA Awards, highlighting its recognition in the healthcare sector [3] Business Strategy - Butterfly combines advanced hardware, intelligent software, AI, services, and education to promote the adoption of affordable imaging solutions [4] - The company aims to democratize healthcare by addressing global healthcare challenges through its cloud-based solutions, which enable care delivery anywhere [4] - Butterfly's devices are available to trained healthcare practitioners across various regions, including Africa, Asia, Europe, and the Americas [4]

Industry Overview - The Medical Services sector is rapidly evolving due to digital health advancements, value-based care adoption, and a focus on patient-centric solutions [1] - The global healthcare analytics market is projected to grow from $56.64 billion in 2025 at a CAGR of 22.7% through 2035, benefiting payers, providers, and analytics vendors [1] - The industry includes various service providers such as pharmacy benefit managers, contract research organizations, and healthcare workforce solution providers, transitioning from volume-based to value-based care [3] Key Trends - The U.S. digital health market is expected to grow from $92.08 billion in 2025 to $248.11 billion by 2034, with a CAGR of 11.6% [4] - The global big data in healthcare market is valued at $110.97 billion in 2025, projected to grow at a CAGR of 19.2% from 2026 to 2035 [4] - Companies adopting AI technologies have seen a 50% reduction in treatment costs and over 50% improvement in patient outcomes [4] Workforce Challenges - A projected healthcare worker shortage of 100,000 by 2028, including a shortfall of 73,000 nursing assistants, is expected to elevate labor costs [2][5] - The WHO estimates a shortfall of 11 million physicians, particularly in low-income countries, emphasizing the need for workforce expansion [5] - Total hospital expenses increased by 5.1% in 2024, significantly outpacing the overall inflation rate of 2.9% [5] Company Highlights - **Medpace Holdings (MEDP)**: Expected earnings growth rate of 17.2% in 2025, with revenues projected to rise by 18.7% from 2024 [19][20] - **Enhabit, Inc. (EHAB)**: Anticipated earnings surge of 161.9% in 2025, with revenue growth of 2.3% [23][24] - **Progyny (PGNY)**: Projected earnings increase of 9.8% in 2025, with revenues expected to grow by 9.2% [26][27] Performance Metrics - The Medical Services industry has gained 6.8% over the past year, in line with the Medical sector, but lagged behind the S&P 500's 19.3% increase [10] - The industry is currently trading at a forward P/E of 16.9X, compared to the S&P 500's 23.3X and the sector's 21.6X [14]